Cargando…

Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment

Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundblad, Victoria, Gomez, Ramiro A., Stupirski, Juan C., Hockl, Pablo F., Pino, Maria S., Laborde, Hugo, Rabinovich, Gabriel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093796/
https://www.ncbi.nlm.nih.gov/pubmed/33959016
http://dx.doi.org/10.3389/fphar.2021.650605
_version_ 1783687890984763392
author Sundblad, Victoria
Gomez, Ramiro A.
Stupirski, Juan C.
Hockl, Pablo F.
Pino, Maria S.
Laborde, Hugo
Rabinovich, Gabriel A.
author_facet Sundblad, Victoria
Gomez, Ramiro A.
Stupirski, Juan C.
Hockl, Pablo F.
Pino, Maria S.
Laborde, Hugo
Rabinovich, Gabriel A.
author_sort Sundblad, Victoria
collection PubMed
description Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Increasing evidence indicates a role for galectins in immune and vascular programs, extracellular matrix remodeling and fibrosis, suggesting their possible involvement in SSc. Here, we determined serum levels of galectin (Gal)-1 and Gal-3 in 83 SSc patients (dcSSc n = 17; lcSSc n = 64; ssSSc n = 2), and evaluated their association with clinical manifestations of the disease. Patients with dcSSc showed lower Gal-3 levels, compared to lcSSc (p = 0.003), whereas no considerable difference in Gal-1 levels was detected between groups. Remarkably, higher concentrations of Gal-1 were associated with the presence of telangiectasias (p = 0.015), and higher concentrations Gal-3 were associated with telangiectasias (p = 0.021), diarrhea (p = 0.039) and constipation (p = 0.038). Moreover, lower Gal-3 levels were associated with the presence of tendinous retractions (p = 0.005). Patients receiving calcium blockers (p = 0.048), methotrexate (p = 0.046) or any immunosuppressive treatment (p = 0.044) presented lower concentrations of Gal-3 compared to those not receiving such treatments. The presence of telangiectasia and the type of SSc maintained their statistical association with Gal-3 (β 0.25; p = 0.022 and β 0.26; p = 0.017, respectively) in multiple linear regression models. In conclusion, serum levels of Gal-3 are associated with clinical manifestations of SSc. Among them, the presence of telangiectasias could be explained by the central role of this lectin in the vascularization programs.
format Online
Article
Text
id pubmed-8093796
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80937962021-05-05 Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment Sundblad, Victoria Gomez, Ramiro A. Stupirski, Juan C. Hockl, Pablo F. Pino, Maria S. Laborde, Hugo Rabinovich, Gabriel A. Front Pharmacol Pharmacology Systemic Sclerosis (SSc) is a rheumatic disease characterized by fibrosis, microvascular damage and immune dysregulation. Two major subsets, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) can be defined, according to the extent of skin involvement. Increasing evidence indicates a role for galectins in immune and vascular programs, extracellular matrix remodeling and fibrosis, suggesting their possible involvement in SSc. Here, we determined serum levels of galectin (Gal)-1 and Gal-3 in 83 SSc patients (dcSSc n = 17; lcSSc n = 64; ssSSc n = 2), and evaluated their association with clinical manifestations of the disease. Patients with dcSSc showed lower Gal-3 levels, compared to lcSSc (p = 0.003), whereas no considerable difference in Gal-1 levels was detected between groups. Remarkably, higher concentrations of Gal-1 were associated with the presence of telangiectasias (p = 0.015), and higher concentrations Gal-3 were associated with telangiectasias (p = 0.021), diarrhea (p = 0.039) and constipation (p = 0.038). Moreover, lower Gal-3 levels were associated with the presence of tendinous retractions (p = 0.005). Patients receiving calcium blockers (p = 0.048), methotrexate (p = 0.046) or any immunosuppressive treatment (p = 0.044) presented lower concentrations of Gal-3 compared to those not receiving such treatments. The presence of telangiectasia and the type of SSc maintained their statistical association with Gal-3 (β 0.25; p = 0.022 and β 0.26; p = 0.017, respectively) in multiple linear regression models. In conclusion, serum levels of Gal-3 are associated with clinical manifestations of SSc. Among them, the presence of telangiectasias could be explained by the central role of this lectin in the vascularization programs. Frontiers Media S.A. 2021-04-20 /pmc/articles/PMC8093796/ /pubmed/33959016 http://dx.doi.org/10.3389/fphar.2021.650605 Text en Copyright © 2021 Sundblad, Gomez, Stupirski, Hockl, Pino, Laborde and Rabinovich. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sundblad, Victoria
Gomez, Ramiro A.
Stupirski, Juan C.
Hockl, Pablo F.
Pino, Maria S.
Laborde, Hugo
Rabinovich, Gabriel A.
Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title_full Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title_fullStr Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title_full_unstemmed Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title_short Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment
title_sort circulating galectin-1 and galectin-3 in sera from patients with systemic sclerosis: associations with clinical features and treatment
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093796/
https://www.ncbi.nlm.nih.gov/pubmed/33959016
http://dx.doi.org/10.3389/fphar.2021.650605
work_keys_str_mv AT sundbladvictoria circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT gomezramiroa circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT stupirskijuanc circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT hocklpablof circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT pinomarias circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT labordehugo circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment
AT rabinovichgabriela circulatinggalectin1andgalectin3inserafrompatientswithsystemicsclerosisassociationswithclinicalfeaturesandtreatment